These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
4. Valsartan in chronic heart failure. Ripley TL Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480 [TBL] [Abstract][Full Text] [Related]
5. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study. Wilting I; Heerdink ER; Mersch PP; den Boer JA; Egberts AC; Nolen WA Bipolar Disord; 2009 Jun; 11(4):434-40. PubMed ID: 19500096 [TBL] [Abstract][Full Text] [Related]
6. Potential drug interaction between lithium and valsartan. Leung M; Remick RA J Clin Psychopharmacol; 2000 Jun; 20(3):392-3. PubMed ID: 10831034 [No Abstract] [Full Text] [Related]
7. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review. Kalra A; Cooley C; Palaniswamy C; Kalra A; Zanotti-Cavazzoni SL Am J Ther; 2012 Nov; 19(6):e189-92. PubMed ID: 20838200 [TBL] [Abstract][Full Text] [Related]
8. Exanthematous drug eruption due to valsartan. Ozturk G; Turk BG; Senturk B; Turkmen M; Kandiloglu G Cutan Ocul Toxicol; 2012 Dec; 31(4):335-7. PubMed ID: 22257082 [TBL] [Abstract][Full Text] [Related]
9. A drug safety evaluation of valsartan. Fogari R; Zoppi A Expert Opin Drug Saf; 2011 Mar; 10(2):295-303. PubMed ID: 21142805 [TBL] [Abstract][Full Text] [Related]
10. Parkinsonism and severe hypothyroidism in an elderly patient: a case of lithium toxicity due to pharmacological interactions. Basile G; Epifanio A; Mandraffino R; Trifirò G J Clin Pharm Ther; 2014 Aug; 39(4):452-4. PubMed ID: 24725285 [TBL] [Abstract][Full Text] [Related]
11. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878 [TBL] [Abstract][Full Text] [Related]
12. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548 [TBL] [Abstract][Full Text] [Related]
13. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516 [TBL] [Abstract][Full Text] [Related]
14. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836 [TBL] [Abstract][Full Text] [Related]
15. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651 [TBL] [Abstract][Full Text] [Related]
17. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report]. Roger N; Popovic I; Madelenat P; Mahieu-Caputo D Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313 [TBL] [Abstract][Full Text] [Related]
18. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280 [TBL] [Abstract][Full Text] [Related]
19. [A case of valsartan-induced pneumonitis with marked elevation of serum KL-6]. Takakura A; Kubota M; Otani S; Katono K; Yamamoto M; Masuda N Nihon Kokyuki Gakkai Zasshi; 2011 Jul; 49(7):523-7. PubMed ID: 21842690 [TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant. White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]